Immuneering Corp — Director's Dealing 2021

Aug 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-08-03

Reporting Person: Feinberg Peter (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-03	Class A Common Stock	C	133572	—	Acquired	257325	Indirect
2021-08-03	Class A Common Stock	P	129167	$15.00	Acquired	386492	Indirect
2021-08-03	Class A Common Stock	C	123155	—	Acquired	347401	Indirect
2021-08-03	Class A Common Stock	P	129167	$15.00	Acquired	476568	Indirect
2021-08-03	Class A Common Stock	C	82108	—	Acquired	82108	Indirect
2021-08-03	Class A Common Stock	P	33333	$15.00	Acquired	115441	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-03	Series A Preferred Stock	$	C	102926	Disposed		Class A Common Stock (102926)	Indirect
2021-08-03	Series A Preferred Stock	$	C	92509	Disposed		Class A Common Stock (92509)	Indirect
2021-08-03	Series A Preferred Stock	$	C	51462	Disposed		Class A Common Stock (51462)	Indirect
2021-08-03	Series B Preferred Stock	$	C	30646	Disposed		Class A Common Stock (30646)	Indirect
2021-08-03	Series B Preferred Stock	$	C	30646	Disposed		Class A Common Stock (30646)	Indirect
2021-08-03	Series B Preferred Stock	$	C	30646	Disposed		Class A Common Stock (30646)	Indirect

Footnotes

F1: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F2: Mr. Feinberg is a General Partner of PF Associates L.P.

F3: Mr. Feinberg is a General Partner of PEF LLC.

F4: Mr. Feinberg is a General Partner of S4K Investments LLC.